<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389074</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMUM</org_study_id>
    <nct_id>NCT03389074</nct_id>
  </id_info>
  <brief_title>Evaluation of Optimal Ablation Index for Pulmonary Vein Isolation in Patients With AF Prospective Registry</brief_title>
  <official_title>Evaluation of OPTIMal Ablation Index for pUlMonary Vein Isolation in Patients With Atrial Fibrillation (OPTIMUM) Prospective Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators identify the optimal AI value for achieving good acute&#xD;
      outcomes in PVI.&#xD;
&#xD;
      Through the Phase 1 study, the investigators will prospectively analyze data including&#xD;
      ablation parameters, AI and acute outcomes of 20 patients performed PVI with conventional&#xD;
      ablation strategy (AI-blinded).&#xD;
&#xD;
      After Phase 1 study results, optimal target AI value for each predefined PV segment will be&#xD;
      determined. Then, by applying optimal AI values derived from the Phase 1 study, the&#xD;
      investigators will evaluate the feasibility of the AI-guided procedure and verify the optimal&#xD;
      AI value for acute PVI outcomes in the prospectively enrolled patients (n = 30) in the Phase&#xD;
      2 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Phase 1 A total of 30 240 patients with AF will be prospectively and consecutively&#xD;
           enrolled and applied conventional ablation strategy with AI-blinded using contact force&#xD;
           sensing catheter (Thermocool SmartTouch Catheter, Biosense Webster Inc.). Conventional&#xD;
           ablation will be performed signal reduction-guided, point by point ablation using&#xD;
           Visitag automated annotation criteria (2520-35W, target contact force 10-20g30g, target&#xD;
           time: 30-40sec for anterior/roof segments, 2015-30sec for posterior/inferior segments).&#xD;
&#xD;
           AI value will be derived from comprehensive off-line analysis of ablation parameters&#xD;
           including contact force, time, power and AI of these 30 240 patients by predefined 14&#xD;
           segments.&#xD;
&#xD;
           Through comparison of AI of each segment with or without acute outcomes including PV&#xD;
           residual potential after first encirclement/early reconnection (ER)/dormant conduction&#xD;
           (DC), minimal AI value would be drawndetermined, and optimal AI value will be suggested&#xD;
           for future AI-guided ablation strategy Phase 2 study (AI-guided ablation strategy).&#xD;
&#xD;
        2. Phase 2 The Phase 2 study aims to evaluate the feasibility of applying optimal AI values&#xD;
           derived from the Phase 1 study, and to verify optimal values through AI-guided ablation.&#xD;
           Thirty patients with AF will be prospectively and consecutively enrolled. AI information&#xD;
           will be opened to the operator during ablation, and Visitag annotation criteria will&#xD;
           also be used for AI-guided ablation with pre-set minimum target values for each segment&#xD;
           derived from the Phase 1 study. After the procedure, the proportion of ablation points&#xD;
           within the target AI value will be calculated by evaluation of the feasibility of the&#xD;
           AI-guided ablation strategy. Acute outcomes of PVI including PV residual potential after&#xD;
           first encirclement, ER, and DC will be evaluated based on predefined segments.&#xD;
&#xD;
        3. Comparison of conventional vs. AI-guided ablation The investigators will compare the&#xD;
           acute outcomes of PVI using two different strategies: conventional vs. AI-guided&#xD;
           ablation. During 1 year of follow-up in both groups, AF recurrence will be evaluated at&#xD;
           3, 6, 9 and 12 months using rhythm surveillance (ECG or 24-hour Holter monitoring). The&#xD;
           AF recurrence rate at 1 year after PVI will be compared between the two groups. In&#xD;
           addition, total ablation time, fluoroscopic time, procedure time, and complication rates&#xD;
           for the index procedure will be compared between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>recurrence of a-fib</measure>
    <time_frame>1 year</time_frame>
    <description>Early recurrence and late recurrence(after 1-year)</description>
  </primary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency catheter ablation</intervention_name>
    <description>minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 to 80 years old&#xD;
&#xD;
          -  Patients with symptomatic paroxysmal or persistent AF who had failed with&#xD;
             anti-arrhythmic agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had previous ablation for AF&#xD;
&#xD;
          -  Patients with left atrial (LA) diameter more than 50mm&#xD;
&#xD;
          -  Inability or unwillingness to receive oral anticoagulation with a Vitamin K antagonist&#xD;
             (VKA)or non-VKA (NOAC) agent&#xD;
&#xD;
          -  Known severe left ventricular systolic function (ejection fraction&lt;35%)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Euekeun Choi, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National university Hostpital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Eue-Keun Choi</investigator_full_name>
    <investigator_title>Associate Professor, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

